Chronic Pain Clinical Trial
— iHOPEOfficial title:
Addressing the Epidemic of Chronic Pain Among Older Adults in Underserved Communities; The GetActive+ Study
Verified date | November 2023 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this project is to conduct an open-pilot (N=30) to evaluate the feasibility, acceptability, and fidelity of a mind-body and activity program (GetActive+) with older adults with chronic pain. The investigators will test for improvements in self-reported, performance-based (i.e., six-minute walk test), and objective (i.e., step-count) physical function, emotional function, as well as feasibility, acceptability and implementation markers. Participants will complete measures at baseline and post-intervention.
Status | Active, not recruiting |
Enrollment | 33 |
Est. completion date | July 1, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: 1. Older Adults (i.e., age >=55) 2. Diagnosed musculoskeletal chronic pain of any type (e.g., pain > 3 months); diagnosed musculoskeletal chronic pain of any type (e.g., pain > 3-6 months) 3. Pain score >=4 (moderate) on the Numerical Rating Scale 4. Cognitively able to participate as measured by the Short Portable Mental Health questionnaires (e.g., <4 errors) 5. No self-reported current active, untreated psychotic or substance use disorder that would interfere with participation in the research study 6. Ability to complete the 6-minute walk test under supervision of study staff 7. Patient at Revere HealthCare Center who is cleared for participation by medical staff 8. English or Spanish fluency Exclusion Criteria: 1. Current serious medical illness that is expected to worsen in the next 6 months (e.g., cancer) 2. Individuals who are unwilling or unable to wear the ActiGraph device |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Greenberg J, Lin A, Popok PJ, Kulich RJ, Edwards RR, Vranceanu AM. Getting Active Mindfully: Rationale and Case Illustration of a Group Mind-body and Activity Program for Chronic Pain. J Clin Psychol Med Settings. 2021 Dec;28(4):706-719. doi: 10.1007/s10880-020-09758-w. Epub 2021 Jan 19. — View Citation
Grunberg VA, Greenberg J, Mace RA, Bakhshaie J, Choi KW, Vranceanu AM. Fitbit Activity, Quota-Based Pacing, and Physical and Emotional Functioning Among Adults With Chronic Pain. J Pain. 2022 Nov;23(11):1933-1944. doi: 10.1016/j.jpain.2022.07.003. Epub 2022 Jul 29. — View Citation
Popok PJ, Greenberg J, Gates MV, Vranceanu AM. A qualitative investigation of activity measurement and change following a mind-body activity program for chronic pain. Complement Ther Clin Pract. 2021 Aug;44:101410. doi: 10.1016/j.ctcp.2021.101410. Epub 2021 May 2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The Interpersonal Support Evaluation List (ISEL-12), | The Interpersonal Support Evaluation List (ISEL-12) measures perceptions of social support. Minimum = 12, Maximum = 48. Higher scores indicate a better outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Pain Catastrophizing Scale (PCS) | The Pain Catastrophizing Scale (PCS) is a 13-item questionnaire assessing one's tendency to focus on pain-related thoughts and feel helpless and hopeless due to pain on a scale of 0 to 4. Higher scores indicate higher pain catastrophizing. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | The Pain, Enjoyment of Life and General Activity scale (PEG) | The Pain, Enjoyment of Life and General Activity scale (PEG) rates a participant's pain intensity and related interference in enjoyment of life and general activity. Minimum = 0, Maximum = 10. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Applied Mindfulness Process Scale (AMPS) | The Applied Mindfulness Process Scale (AMPS) assesses how participants use mindfulness when facing challenges in daily life. Sum all 15 items to obtain a total score ranging from 0-60. Higher scores indicate higher utilization of mindfulness | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Cognitive and Affective Mindfulness Scale - Revised (CAMS-R) | Cognitive and Affective Mindfulness Scale - Revised (CAMS-R) rates a participant's broad conceptualization of mindfulness,. Minimum = 12 Maximum = 48. Higher values reflect higher levels of mindfulness. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Perceived Stress Scale (PSS-4) | The Perceived Stress Scale (PSS-4) assesses stress perception levels. Total sum of scores. Minimum = 0 Maximum =16; Higher scores are correlated to more stress. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | The Post-Traumatic Checklist-Civilian Version-6 (PCL-C short form) | The Post-Traumatic Checklist-Civilian Version-6 (PCL-C short form) assess current Post Traumatic Stress Disorder symptoms. Higher scores are suggestive of difficulties with post-traumatic stress and further assessment and possibly referral for treatment is indicated. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Contrast Avoidance Questionnaire - Shortened (CAQ-S) | Contrast Avoidance Questionnaire - Shortened (CAQ-S) a measure of sustaining negative emotionality to protect against sudden shifts in emotion. Minimum = 8, Maximum = 40 with higher scores indicating worse outcomes. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Patient Global Impression of Change (PGIC) | The Patient Global Impression of Change (PGIC) measures changes in pain in response to treatment. Minimum = 0, Maximum = 6. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Tampa Scale for Kinesiophobia-11 (TSK11) | The Tampa Scale for Kinesiophobia-11 (TSK11) is an 11-item questionnaire that assesses fear avoidance and fear of activity. Summary score of total responses with Minimum = 11 and Maximum = 44. Higher scores indicate higher kinesiophobia. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | UCLA-3 Loneliness Scale | The UCLA-3 Loneliness Scale measures isolation / perceived lack of social connectedness. Minimum = 3, Maximum = 9. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Self-Compassion Scale - Short Form (SCS-SF) | The Self-Compassion Scale - Short Form (SCS-SF) is the rate of a participant's amount of self-compassion. Scores are calculated by averaging the 12 items with Minimum = 1, Maximum = 5. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Gratitude Questionnaire (GQ-6) | The Gratitude Questionnaire (GQ-6) assesses individual differences in the proneness to experience gratitude in daily life. Total summary of score with a Minimum = 6, Maximum = 42. Higher score indicating greater amount of gratitude. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Measure of Current Status (MOCS) | The MOCS questionnaire assesses ability to engage in a series of healthy coping skills (e.g., relaxation, social support, adaptive thinking). Minimum = 0, maximum = 52. Higher scores indicate better outcome and a stronger ability to recognize stress and cope. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) | The Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) assess substance use behaviors. No summary score. Each item is scored individually for each substance. For each item, higher scores indicate better outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | The Everyday Discrimination Scale - Short (EDS-S) | The Everyday Discrimination Scale - Short (EDS-S) assesses experiences of discrimination. Responses are summed across items with a Minimum = 10, Maximum = 60. Higher scores indicate greater frequency of discriminatory experiences. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | PROMIS Sleep Disturbance - Short Form 6a v1.0; | The PROMIS Sleep Disturbance - Short Form 6a v1.0 assesses quality of sleep. Sleep disturbance with a Minimum = 6, Maximum = 30. Higher scores indicate worse outcomes. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | The Pittsburgh Sleep Quality Index (PSQI) | The Pittsburgh Sleep Quality Index (PSQI) is a single item (item 4) from PSQI assessing sleep duration with Minimum = 0 and Maximum = 24 (hour and minutes per night). | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Other | Qualitative Assesment | We will collect qualitative data from patients through exit interviews assessing perceptions of intervention. | Post-test (1 week after intervention completion) | |
Other | Pain, medication, and medical history questionnaire (PMMH) | The Pain, medication, and medical history questionnaire (PMMH) assesses self-reported type of pain; pain location and number; pain treatments; pain medications; cannabis use for pain; medical comorbidities; mental health conditions and medication. There is no summary score, each item scored individually. | Post-test (1 week after intervention completion) | |
Primary | Feasibility of intervention completion | >=75 of patients approached agree to participate in intervention | 10 weeks | |
Secondary | Physical function, performance-based | 6-minute walk test (6MWT), assesses distance walked in 6 minutes. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Physical function - objective | Average step count with ActiGraph GT3X-BTLE | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Short Form Brief Pain Inventory (BPI) pain severity and interference subscales | The Short Form Brief Pain Inventory (BPI) pain severity subscale assesses pain at its worst, least, average, and current. Minimum = 0, maximum = 10. Higher scores indicate worse outcome. The interference subscale assesses pain interference in the last 24 hours. Minimum = 0, maximum = 10. Higher scores indicate worse interference. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Patient Health Questionnaire-8 (PHQ-8) | The Patient Health Questionnaire (PHQ-8) is an assessment of depressive symptoms. Total summary score with Minimum = 0, Maximum = 24. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Generalized Anxiety Disorder scale-7 (GAD-7); | The Generalized Anxiety Disorder scale-7 (GAD-7) is an assessment of generalized anxiety symptoms. GAD-7 total score is obtained by adding the score for each of the items. Minimum = 0, Maximum = 21. Scores of 5-9 (mild), 10-14 (moderate), and 15-21 (severe) represent thresholds for mild, moderate, and severe anxiety. Higher scores indicate worse outcome. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Physical function self-report | Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Functioning Short Form 6b, self-report ability to engage in physical activities. Total summary score with Minimum = 8, Maximum = 40. Higher scores reflect greater physical function. | Baseline (0 weeks), Post-test (1 week after intervention completion) | |
Secondary | Acceptability | Satisfaction with or tolerability of the proposed approach >=75% of enrolled participants complete at least 8/10 sessions. | 10 weeks | |
Secondary | Fidelity | >=75% of GetActive+ sessions components delivered as intended; 20% sessions rated | 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|